Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Gene Therapy for treatment of rare inherited Arrhythmogenic Cardiomyopathy

Project description

Heart of the problem: targeted gene therapy for ACM

Developing treatments for rare heart diseases is often slow and costly due to insufficient insight into how these conditions work. The EU-funded GEREMY project aims to overcome this by creating a curative gene therapy for inherited arrhythmogenic cardiomyopathy (ACM). By targeting specific genetic mutations (PLN and PKP2), researchers use advanced gene-editing and delivery methods to correct defects and restore heart muscle function. The project will also develop new disease models, ensure safety through rigorous testing, prepare for future clinical trials and align with patient needs. Ultimately, GEREMY seeks to transform patient care, significantly reducing healthcare burdens and providing a roadmap for treating other genetic heart conditions.

Objective

Development of a cure for rare cardiac diseases is a risky, costly and time-consuming process, which is hampered by insufficient insight into pathophysiological mechanisms of the diseases and lack of relevant disease models.
The GEREMY consortium proposes to overcome this challenge by developing a gene therapy (GT) for inherited arrhythmogenic cardiomyopathy (ACM), by targeting the disease-causing PLN (non-desmosomes) and PKP2 (cardiac desmosomes) mutations. The GEREMY consortium will apply a unique parallel approach and investigate various promising GT approaches (oligonucleotide chemistries, gene editing and gene delivery). Also, the consortium will engineer disease models for proper assessment of therapeutic interventions and aims to provide in vitro & in vivo preclinical proof-of-concept for the GT.
A significant benefit compared to current technologies is that the GT has the potential to be a curative treatment for rare cardiac diseases. Based on previous successes, GEREMY will target PLN & PKP2 as a roadmap of the technology. Restoring the primary defect in the PLN & PKP2 genes that cause the disease will lead to preserving or even restoring myocardial contractility. Through this approach, GEREMY will work towards a curative treatment of inherited ACM and likely other cardiomyopathies, which significantly reduces the healthcare burden.
The project’s experts in preclinical research and cardiac genetics will deliver preclinical efficacy and safety data for the mutation correction. The partners with regulatory and clinical trial expertise (EXOM, EUF, NLHI) will prepare for immediate start of clinical trials upon project completion, and apply for orphan drug designation. EUPATI, a patient organisation and KUL ethics partner will ensure that the project is continuously aligned with patient needs and ethical perspectives. The whole consortium will contribute to communicate an disseminate the results to ensure maximum exploitation of this breakthrough technology.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2022-DISEASE-06-two-stage

See all projects funded under this call

Coordinator

STICHTING NETHERLANDS HEART INSTITUTE
Net EU contribution
€ 1 312 250,00
Address
MOREELSEPARK 1
3511 EP UTRECHT
Netherlands
Activity type
Research Organisations
Links
Total cost
€ 1 312 250,00

Participants (9)

Partners (1)